tirzepatide side effects kidney Associated with Lower Risk of Heart and Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease Tirzepatide: How to Use It

The prevalence of obesity is steadily increasing both in Korea and worldwide

Orforglipron has shown statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in a successful Phase III trial

This shift could reflect a changing demand away from oncology toward addressing metabolic disorders. Leading the charge in the GLP1 market are five key drugs: Mounjaro, Ozempic, Wegovy, Cagrisema, and Rybelsus, which are forecast to capture 83 per cent of the GLP-1 agonist market by 2029

The cumulative incidence was 8.9% for semaglutide, compared to 1.8% for non-GLP-1 RA over 36 months

Mai 2024, ISSN 2041-1723, S